Preliminary Safety And Efficacy Of Gx-17, A Long-Acting Interleukin-7, In Combination With Pembrolizumab In Patients With Refractory Or Recurrent Metastatic Triple Negative Breast Cancer (Mtnbc): Dose Escalation Period Of Phase Ib/Ii Study (Keynote-899).

Joohyuk Sohn,Kyong Hwa Park,Hee Kyung Ahn,Keun Seok Lee,Jee Hyun Kim,Sung-Bae Kim,Kyoung Eun Lee,Jee Hung Kim,Se Hwan Yang,Ngocdiep T. Le,Jiwon Kim,MinKyu Heo,Jung-Won Woo,Young Chul Sung,Young Hyuck Im

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 4|浏览46

暂无评分

摘要

1072Background: Pembrolizumab monotherapy did not significantly improve OS as 2nd and 3rd-lines treatment for mTNBC compared to standard chemotherapy in phase III study (KEYNOTE-119) leading to hig...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要